We are committed to working with you to improve the quality of care and health outcomes for our members, your patients. HEDIS® (Healthcare Effectiveness Data and Information Set) is one tool we use to measure many aspects of performance. This document details some of the key features of the HEDIS Measure for Non-Recommended Prostate-Specific Antigen (PSA)-Based Screening in Older Men.

**What is the measure?**
This claims-based measure reports the percentage of men 70 years and older who were screened unnecessarily for prostate cancer using PSA-based screening.

**Note:** A lower rate indicates better performance.

The U.S. Preventive Services Task Force (USPSTF) evaluated research for prostate cancer screening and recommends against screening—assigning a Grade D (for screening)—and stating that the science shows that more men will be harmed by PSA screening than will benefit.

The USPSTF’s recommendations suggest routine testing would detect too many slow-growing tumors that would:

- otherwise not pose a threat to healthy men
- lead to over treatment with radiation and surgery
- lead to other complications, such as erectile dysfunction and incontinence.

There are situations by which a PSA-based testing is clinically appropriate, and a claims-based exclusion process is used to identify valid exclusions.

### Eligible Members
- Members who are age 70 or older as of December 31 of the measurement year
- Continuously enrolled during the measurement year

*(continued next page)*
HEDIS Measure: Non-Recommended Prostate-Specific Antigen (PSA)-Based Screening in Older Men (continued)

### Measurement Details

**Numerator:** PSA-based screening test performed during the measurement year

**Denominator:** Men who have been continuously enrolled during the measurement year and are age 70 or older as of December 31 of the measurement year (see exclusions).

### Exclusions

Claims based exclusions are identified for the following cases in which PSA-screening does not count in this measure. In some cases, medical record documentation is also permitted, when:

<table>
<thead>
<tr>
<th>Exclusion</th>
<th>Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate cancer diagnosis</td>
<td>Prostate cancer diagnosis any time during the member’s history. Claims or medical record documentation accepted.</td>
</tr>
<tr>
<td>Dysplasia of the prostate during the measurement year or the year prior to the measurement year</td>
<td>Claims or medical record documentation accepted.</td>
</tr>
<tr>
<td>A PSA test during the measurement year, where the laboratory data indicate an elevated result (&gt;4.0ng/mL)</td>
<td>Claims, lab results received by Florida Blue, or medical record documentation accepted.</td>
</tr>
<tr>
<td>Dispensed prescription for 5-alpha reductase inhibitor during the measurement year</td>
<td>Prescription for finasteride or dutasteride during the measurement year, identified through pharmacy claims. Other documentation indicating patient picked up a pharmacy prescription is accepted provided it indicates date of dispensing.</td>
</tr>
</tbody>
</table>